Aloe Vera-Containing Matrix in Transdermal Fentanyl Therapy
                    Improves Adhesion, Skin Tolerance and Quality of Life: Results of a German
                    Multicenter Study with a New Fentanyl Patch

Christoph G. Dietrich; Tanja Kottmann; Hans Werner Voß; Roxane Lorenz

doi:10.1055/a-1960-2879

Drug Research, Inhaltsverzeichnis

Drug Res (Stuttg) 2023; 73(02): 70-74
DOI: 10.1055/a-1960-2879

Original Article

Aloe Vera-Containing Matrix in Transdermal Fentanyl Therapy Improves Adhesion, Skin Tolerance and Quality of Life: Results of a German Multicenter Study with a New Fentanyl Patch

Christoph G. Dietrich

¹Bethlehem Health Center, Department of Internal Medicine, Stolberg/Rhld

,

Tanja Kottmann

²CRO Dr. med. Kottmann, Hamm/Westf

,

Hans Werner Voß

²CRO Dr. med. Kottmann, Hamm/Westf

,

Roxane Lorenz

³Dr. Ausbüttel Pharma GmbH, Dortmund, all in Germany

› Institutsangaben

Abstract

Background Chronic pain represents a significant and costly healthcare problem especially in the older patient. Transdermal opioid therapy is easy to apply and ensures constant supply of active ingredients. However, skin irritation, poor adhesion and systemic side effects complicate transdermal pain therapy.

Methods In the Relief study, comprising 54 centers, all in Germany, 252 patients were recruited and data about the general care situation as well as the characteristics, effects and side effects of the Aloe vera fentanyl patch were collected. 92 patients had a prior treatment with fentanyl patch without Aloe vera, allowing a comparative analysis.

Results Compared to patches without Aloe vera, the new fentanyl patch showed better adhesion. Systemic and local tolerance and pain reduction were also significantly better. Patients also reported improvements in side effects and central parameters of quality of life. The data regarding the care situation in Germany showed remarkably low use of coanalgetics and laxatives in pain patients.

Discussion Aloe vera in transdermal pain treatment improves adhesion and local tolerance of the patch. Pain control and quality of life were also improved. Regional care data concerning cotreatment in pain therapy from this study indicate a lack of penetration of existing guidelines in general practitioners’ pain therapy.

Key words

Pain - fentanyl - Aloe vera - care situation - adhesion - side effects

Volltext

Referenzen

References
1 van Hecke O, Torrance N, Smith BH. Chronic pain epidemiology and its clinical relevance. Br J Anaesth 2013; 111: 13-18
2 Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333
3 Sanzarello I, Merlini L, Rosa MA. et al. Central sensitization in chronic low back pain: A narrative review. J Back Musculoskelet Rehabil 2016; 29: 625-633
4 Chou R, Fanciullo GJ, Fine PG. et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-130
5 Breivik H, Cherny N, Collett B. et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009; 20: 1420-1433
6 Johnson M, Collett B, Castro-Lopes JM. The challenges of pain management in primary care: a pan-European survey. J Pain Res 2013; 6: 393-401
7 Weber C, Reinecke H, Simon M, Lange K, Sorgatz H. Opioid guidelines: yesterday and today: current guideline recommendations for chronic non-tumor pain. Anaesthesist 2012; 61: 625-629
8 Häuser W, Bock F, Hüppe M. et al. Recommendations of the second update of the LONTS guidelines: Long-term opioid therapy for chronic noncancer pain. Schmerz 2020; 34: 204-244
9 Heim M. Noninterventional study of transdermal fentanyl (fentavera) matrix patches in chronic pain patients: analgesic and quality of life effects. Pain Res Treat 2015; 2015: 198343
10 Kress HG, Von der Laage D, Hoerauf KH. et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage 2008; 36: 268-279
11 Schmid-Grendelmeier P, Pokorny R, Gasser UE, Richarz U. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Curr Med Res Opin 2006; 22: 501-509
12 Pergolizzi J, Böger RH, Budd K. et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 8: 287-313
13 Foster M, Hunter D, Samman S. Evaluation of the Nutritional and Metabolic Effects of Aloe vera. In: Benzie IFF, Wachtel-Galor S, eds. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. CRC Press/Taylor & Francis; Boca Raton (FL): 2011
14 Bausewein C, Simon ST, Pralong A, Radbruch L, Nauck F, Voltz R. Palliative Care of Adult Patients With Cancer. Dtsch Arztebl Int 2015; 112: 863-870
15 Tassinari D, Sartori S, Tamburini E. et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 2008; 11: 492-501
16 Gatti A, Longo G, Sabato E, Sabato AF. Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. Eur Neurol 2011; 65: 317-322
17 Barkin RL, Barkin SJ, Irving GA, Gordon A. Management of chronic noncancer pain in depressed patients. Postgrad Med 2011; 123: 143-154
18 Derry S, Stannard C, Cole P. et al. Fentanyl for neuropathic pain in adults. Cochrane Database Syst Rev 2016; 10: CD011605